140 related articles for article (PubMed ID: 29448045)
1. Serum ARCHITECT PIVKA-II reference interval in healthy Chinese adults: Sub-analysis from a prospective multicenter study.
Yan C; Hu J; Yang J; Chen Z; Li H; Wei L; Zhang W; Xing H; Sang G; Wang X; Han R; Liu P; Li Z; Li Z; Huang Y; Jiang L; Li S; Dai S; Wang N; Yang Y; Ma L; Soh A; Beshiri A; Shen F; Yang T; Fan Z; Zheng Y; Chen W
Clin Biochem; 2018 Apr; 54():32-36. PubMed ID: 29448045
[TBL] [Abstract][Full Text] [Related]
2. A multicenter study on PIVKA reference interval of healthy population and establishment of PIVKA cutoff value for hepatocellular carcinoma diagnosis in China.
Qin X; Tang G; Gao R; Guo Z; Liu Z; Yu S; Chen M; Tao Z; Li S; Liu M; Wang L; Hou L; Xia L; Cheng X; Han J; Qiu L
Int J Lab Hematol; 2017 Aug; 39(4):392-401. PubMed ID: 28318145
[TBL] [Abstract][Full Text] [Related]
3. Serum reference interval of ARCHITECT alpha-fetoprotein in healthy Chinese Han adults: Sub-analysis of a prospective multi-center study.
Yan C; Yang J; Wei L; Hu J; Song J; Wang X; Han R; Huang Y; Zhang W; Soh A; Beshiri A; Fan Z; Zheng Y; Chen W
Clin Biochem; 2018 Feb; 52():164-166. PubMed ID: 29129627
[TBL] [Abstract][Full Text] [Related]
4. Analytical and Clinical Performance Evaluation of the Abbott Architect PIVKA Assay.
Ko DH; Hyun J; Kim HS; Park MJ; Kim JS; Park JY; Shin DH; Cho HC
Ann Clin Lab Sci; 2018 Jan; 48(1):75-80. PubMed ID: 29531000
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic performance of tumor markers AFP and PIVKA-II in Chinese hepatocellular carcinoma patients.
Huang S; Jiang F; Wang Y; Yu Y; Ren S; Wang X; Yin P; Lou J
Tumour Biol; 2017 Jun; 39(6):1010428317705763. PubMed ID: 28621228
[TBL] [Abstract][Full Text] [Related]
6. Performance evaluation of serum PIVKA-II measurement using HISCL-5000 and a method comparison of HISCL-5000, LUMIPULSE G1200, and ARCHITECT i2000.
Ryu MR; Kang ES; Park HD
J Clin Lab Anal; 2019 Jul; 33(6):e22921. PubMed ID: 31131509
[TBL] [Abstract][Full Text] [Related]
7. A Novel Online Calculator Based on Serum Biomarkers to Detect Hepatocellular Carcinoma among Patients with Hepatitis B.
Yang T; Xing H; Wang G; Wang N; Liu M; Yan C; Li H; Wei L; Li S; Fan Z; Shi M; Chen W; Cai S; Pawlik TM; Soh A; Beshiri A; Lau WY; Wu M; Zheng Y; Shen F
Clin Chem; 2019 Dec; 65(12):1543-1553. PubMed ID: 31672853
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic value of serum PIVKA-II levels for BCLC early hepatocellular carcinoma and correlation with HBV DNA.
Wu J; Xiang Z; Bai L; He L; Tan L; Hu M; Ren Y
Cancer Biomark; 2018; 23(2):235-242. PubMed ID: 30103302
[TBL] [Abstract][Full Text] [Related]
9. PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinoma.
Feng H; Li B; Li Z; Wei Q; Ren L
BMC Cancer; 2021 Apr; 21(1):401. PubMed ID: 33849479
[TBL] [Abstract][Full Text] [Related]
10. Protein induced by vitamin K absence or antagonist-II (PIVKA-II) specifically increased in Italian hepatocellular carcinoma patients.
Viggiani V; Palombi S; Gennarini G; D'Ettorre G; De Vito C; Angeloni A; Frati L; Anastasi E
Scand J Gastroenterol; 2016 Oct; 51(10):1257-62. PubMed ID: 27227515
[TBL] [Abstract][Full Text] [Related]
11. Development and evaluation of analytical performance of a fully automated chemiluminescent immunoassay for protein induced by vitamin K absence or antagonist II.
Fujita K; Kinukawa H; Ohno K; Ito Y; Saegusa H; Yoshimura T
Clin Biochem; 2015 Dec; 48(18):1330-6. PubMed ID: 26210849
[TBL] [Abstract][Full Text] [Related]
12. Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study.
Kim HS; Park JW; Jang JS; Kim HJ; Shin WG; Kim KH; Lee JH; Kim HY; Jang MK
J Clin Gastroenterol; 2009; 43(5):482-8. PubMed ID: 19197197
[TBL] [Abstract][Full Text] [Related]
13. Epitope characterization of an anti-PIVKA-II antibody and evaluation of a fully automated chemiluminescent immunoassay for PIVKA-II.
Kinukawa H; Shirakawa T; Yoshimura T
Clin Biochem; 2015 Nov; 48(16-17):1120-5. PubMed ID: 26297114
[TBL] [Abstract][Full Text] [Related]
14. The clinical application of PIVKA-II in hepatocellular carcinoma and chronic liver diseases: A multi-center study in China.
Ji J; Liu L; Jiang F; Wen X; Zhang Y; Li S; Lou J; Wang Y; Liu N; Guo Q; Jia Y; Gao C
J Clin Lab Anal; 2021 Nov; 35(11):e24013. PubMed ID: 34590755
[TBL] [Abstract][Full Text] [Related]
15. Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II.
Caviglia GP; Abate ML; Gaia S; Petrini E; Bosco C; Olivero A; Rosso C; Ciancio A; Pellicano R; Saracco GM; Rizzetto M; Smedile A
Panminerva Med; 2017 Dec; 59(4):283-289. PubMed ID: 28650134
[TBL] [Abstract][Full Text] [Related]
16. Modeling the time-related fluctuations of AFP and PIVKA-II serum levels in patients with cirrhosis undergoing surveillance for hepatocellular carcinoma.
Ricco G; Cosma C; Bedogni G; Biasiolo A; Guarino M; Pontisso P; Morisco F; Oliveri F; Cavallone D; Bonino F; Plebani M; Brunetto MR
Cancer Biomark; 2020; 29(2):189-196. PubMed ID: 32623383
[TBL] [Abstract][Full Text] [Related]
17. The Diagnostic Value of Serum PIVKA-II Alone or in Combination with AFP in Chinese Hepatocellular Carcinoma Patients.
Xu F; Zhang L; He W; Song D; Ji X; Shao J
Dis Markers; 2021; 2021():8868370. PubMed ID: 33628341
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic value of AFP-L3 and PIVKA-II in hepatocellular carcinoma according to total-AFP.
Choi JY; Jung SW; Kim HY; Kim M; Kim Y; Kim DG; Oh EJ
World J Gastroenterol; 2013 Jan; 19(3):339-46. PubMed ID: 23372355
[TBL] [Abstract][Full Text] [Related]
19. Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma.
Cui R; Wang B; Ding H; Shen H; Li Y; Chen X
Chin Med J (Engl); 2002 Jan; 115(1):42-5. PubMed ID: 11930656
[TBL] [Abstract][Full Text] [Related]
20. PIVKA-II as a Potential New Biomarker for Hepatocellular Carcinoma - A Pilot Study.
Svobodova S; Karlikova M; Topolcan O; Pecen L; Pestova M; Kott O; Treska V; Slouka D; Kucera R
In Vivo; 2018; 32(6):1551-1554. PubMed ID: 30348715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
